ライフサイエンスコーパス: serious adverse event

1 of whom experienced an intervention-related serious adverse event.

2 the pazopanib group had a pazopanib-related serious adverse event.

3 ed to improve understanding of this rare but serious adverse event.

4 ments were well tolerated, and there were no serious adverse events.

5 (10%) of 105 patients had treatment-related serious adverse events.

6 no significant between-group differences in serious adverse events.

7 (47%) of 99 in the 3.4 mg/kg cohort reported serious adverse events.

8 y dysplasia, or death or in the frequency of serious adverse events.

9 erventional management, with a lower risk of serious adverse events.

10 ry alone group died due to treatment-related serious adverse events.

11 ailty, quality of life, adverse effects, and serious adverse events.

12 ur (12%) patients experienced a total of six serious adverse events.

13 was well tolerated with no treatment-related serious adverse events.

14 three in the gemogenovatucel-T group) had 11 serious adverse events.

15 ent interactions have the potential to cause serious adverse events.

16 are safe procedures with a low incidence of serious adverse events.

17 tion was the most frequent reason leading to serious adverse events.

18 ere no clinically relevant treatment-related serious adverse events.

19 reme symptoms) at 24 weeks of follow-up, and serious adverse events.

20 well tolerated, was not associated with any serious adverse events.

21 and safety, as measured by the occurrence of serious adverse events.

22 follow-up; secondary outcomes were death and serious adverse events.

23 recovery rates were high, with a low rate of serious adverse events.

24 had study drug-related or procedure-related serious adverse events.

25 rly after two of the four patients developed serious adverse events.

26 edure-related and cryoballoon system-related serious adverse events.

27 Huntington's disease was not accompanied by serious adverse events.

28 Stroke Scale worsening and the proportion of serious adverse events.

29 and increased ICS dose increased risk of non-serious adverse events.

30 and produce between three and ten additional serious adverse events.

31 come was the incidence of composite thoracic serious adverse events.

32 , and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events.

33 c drugs on cardiac contractility can lead to serious adverse events.

34 All subjects completed the study without any serious adverse events.

35 s limited, it indicated no increased risk of serious adverse events.

36 sion at week 12 but was associated with more serious adverse events.

37 lement for MPOD volume and SC levels without serious adverse events.

38 ences of malaria, vaso-occlusive crises, and serious adverse events.

39 and safety, as measured by the occurrence of serious adverse events.

40 lar numbers of donor-specific antibodies and serious adverse events.

41 There were no intervention-related serious adverse events.

42 mes included cumulative incidence rates for (serious) adverse events.

43 y analyses were done for number and type of (serious) adverse events.

44 o participants (4%) in the surgery group had serious adverse events (1 had a myocardial infarction on

45 cross genotypes, and low short-term rates of serious adverse events (1.9%) and withdrawal due to adve

46 was well tolerated, with a low incidence of serious adverse events (16%).

47 43.9% [43/98] vs 25.5% [25/98]; P = .01) and serious adverse events (27.6% [27/98] vs 12.2% [12/98];

48 Few participants in either group had serious adverse events (3 [2.4%] vs. 5 [4.0%]).

49 3 participants in the placebo group reported serious adverse events (94 events in the cytisine group

50 4%) in the control group reported at least 1 serious adverse event (adjusted RR, 1.72 [95% CI, 0.7 to

51 tinence, daily cigarette consumption change, serious adverse events, adverse events, dropouts due to

52 Serious adverse events (AEs) occurred in 10% of imipenem

53 Serious adverse events (AEs) occurred in 26.7% of imipen

54 No serious adverse events (AEs) related to treatment were r

55 te the existing evidence for serious and non-serious adverse events after ivermectin exposure in preg

56 amounts, reduce time to recovery, and reduce serious adverse events among hospitalized patients not r

57 The fluvoxamine group had 1 serious adverse event and 11 other adverse events, where

58 erse events, whereas the placebo group had 6 serious adverse events and 12 other adverse events.

59 years in the placebo group; the incidence of serious adverse events and adverse events leading to wit

60 sivir probably improves recovery and reduces serious adverse events and may reduce mortality and time

61 17 (40%) patients had serious adverse events and nine (21%) had treatment-rela

62 There were no drug-related serious adverse events and no treatment-related deaths.

63 ts included proportions of participants with serious adverse events and symptomatic virologically con

64 nation was well tolerated: there were only 2 serious adverse events, and grade 4 toxicity was almost

65 dose, including solicited adverse events and serious adverse events, and immunogenicity (seroprotecti

66 s reported adverse events, 82 (39%) reported serious adverse events, and there were 23 (11%) deaths.

67 There were no serious adverse events, and treatment was associated wit

68 fe-threatening bleeding; any adverse events; serious adverse events; and any bleeding events.

69 rare, with generally no group differences in serious adverse events, any adverse events, hospitalizat

70 8 (2%) of 396 patients given placebo, had a serious adverse event as determined by clinicians.

71 s, congenital anomalies, and neonatal death (serious adverse events), as well as maternal morbidity,

72 Although cardiotoxicity is a serious adverse event associated with several KIs, the r

73 o clinically relevant safety concerns and no serious adverse events associated with metformin.

74 No serious adverse events attributed to ruxolitinib were ob

75 Remdesivir probably reduces serious adverse events by a moderate amount (ARD range,

76 onsidered, including general adverse events, serious adverse events, cognitive impairment, fractures,

77 7 mothers in the dolutegravir group reported serious adverse events compared with 14 (11%) of 131 in

78 ssociated with an increased risk of death or serious adverse events compared with allopurinol.

79 VBL carries a higher risk of serious adverse events compared with NSBB.

80 gulation), we found no difference in risk of serious adverse events, complete resection rate, or poly

81 Serious adverse events (CTCAE grade 4 or 5) occurred in

82 At least 1 serious adverse event developed in 12 patients (24%) in

83 30%) in the placebo group (with 6 infectious serious adverse events developing among 4 patients [9%])

84 te nomograms to calculate the probability of serious adverse events during OFC for individual patient

85 There were four serious adverse events during the study, two (1%) report

86 The incidence of serious adverse events during the treatment period range

87 measure was clinical relapse, defined as any serious adverse event (e.g., suicide, psychiatric hospit

88 Peri-prosthetic joint infections (PJI) are a serious adverse event following joint replacement surger

89 Serious adverse events (four cases of postpolypectomy bl

90 surgery group died due to treatment-related serious adverse events (gastropleural fistula), and no p

91 mg three times weekly group; the most common serious adverse event (>=10% patients in any group) was

92 Pneumonia was reported as a serious adverse event in 0.9% of the patients in the col

93 icipants randomised to rosuvastatin, and one serious adverse event in each group.

94 Pneumonia was the only serious adverse event in more than 2% of patients (seven

95 More women had a serious adverse event in the gabapentin group than in th

96 One serious adverse event in the sertraline group was classi

97 26 serious adverse events in 20 (13%) patients occurred dur

98 of 147 patients in the riluzole group and 34 serious adverse events in 29 (19%) of 153 patients in th

99 There were 43 serious adverse events in 33 (22%) of 147 patients in th

100 tment-emergent adverse events, including six serious adverse events in five patients and 13 discontin

101 Serious adverse events in the intervention and usual car

102 Serious adverse events in the lower-threshold group incl

103 There were 33 (0.05%) serious adverse events in the sigmoidoscopy group compar

104 Nine patients experienced serious adverse events in the single-agent cohort, most

105 The most frequently reported serious adverse events (in two or more patients) were pn

106 Serious adverse events included 1 suicide attempt, relat

107 The outcomes of these serious adverse events included 16 deaths, 4 of which we

108 ts, 7 (4.3%) experienced BAT product-related serious adverse events, including 1 (0.6%) report each o

109 participants of 3489 who initiated PrEP had serious adverse events, including seven deaths.

110 The primary safety end point, serious adverse events involving the arteriovenous acces

111 energy and vitality, depression, cognition, serious adverse events, major adverse cardiovascular eve

112 139 (83%) of 168 patients had serious adverse events, most frequently neutropenic feve

113 regimen was safe, with no treatment-related serious adverse events observed.

114 One serious adverse event occurred in each group (one cardia

115 No related serious adverse events occurred during the second year.

116 Three serious adverse events occurred during the study (pulmon

117 As of Oct 26, 2020, 13 serious adverse events occurred during the study period,

118 Serious adverse events occurred equally between groups.

119 Serious adverse events occurred in 10% of participants o

120 Serious adverse events occurred in 11 patients (17%) in

121 Serious adverse events occurred in 115 (34%) patients in

122 Serious adverse events occurred in 115 (54%) of 212 pati

123 Nonfatal serious adverse events occurred in 12/72 (16.7%) in the

124 Serious adverse events occurred in 190 (42.5%) patients

125 Serious adverse events occurred in 22.7% and 21.7%, resp

126 Serious adverse events occurred in 24 (32%) patients in

127 Treatment-related serious adverse events occurred in 25 (24%) patients and

128 Serious adverse events occurred in 250 (45%) of 559 pati

129 Serious adverse events occurred in 3 patients (2.6%) in

130 Serious adverse events occurred in 33 (10%) of 332 patie

131 e events were balanced and treatment-related serious adverse events occurred in 37 (23%) and 26 (16%)

132 In the safety population, serious adverse events occurred in 38 of 250 patients (1

133 Serious adverse events occurred in 4 patients (9%) in th

134 Serious adverse events occurred in 4.8% (2 of 42), 2.4%

135 Serious adverse events occurred in 41 (51%) of 81 patien

136 Serious adverse events occurred in 42 (54%) of 78 patien

137 Serious adverse events occurred in 43 (33%) of 132 patie

138 Serious adverse events occurred in 5 patients (3.2%) who

139 Nine serious adverse events occurred in 6 participants (1 in

140 Serious adverse events occurred in 63 (46%) participants

141 Serious adverse events occurred in 7.2% of patients in t

142 Up to week 24, serious adverse events occurred in eight (3%) of 245 pat

143 Serious adverse events occurred in five (4%) patients, i

144 All 14 serious adverse events occurred in patients who received

145 Treatment-related serious adverse events occurred in seven (12%) patients

146 Treatment-related serious adverse events occurred in six (14%) of 42 patie

147 Three serious adverse events occurred in the biomechanical foo

148 Two serious adverse events occurred in the eltrombopag group

149 Five serious adverse events occurred in the intravenous immun

150 Serious adverse events occurred in the pridopidine group

151 Serious adverse events occurred in three of seven patien

152 Treatment-related serious adverse events occurred in two patients (one sei

153 Serious adverse events occurred in two patients patients

154 During the long-term follow-up, no serious adverse events occurred that were deemed related

155 No intervention-related serious adverse events occurred, and few adverse effects

156 Four non-DBS-related serious adverse events occurred, including one suicide a

157 %) in the rituximab group (with 9 infectious serious adverse events occurring among 6 patients [12%])

158 One 3-year-old patient had a serious adverse event of accidental ribavirin overdose r

159 The most common serious adverse events of any grade in the ramucirumab p

160 d well tolerated with no causally associated serious adverse events or important medical events in an

161 ative management resulted in a lower risk of serious adverse events or pneumothorax recurrence than i

162 No vaccine-related serious adverse events or severe dengue virus disease we

163 No serious adverse events or treatment-emergent adverse eve

164 rse events (OR 2.65, 95% CI: 1.04-6.80), any serious adverse event (OR 2.30, 95% CI: 1.18-4.48), seri

165 had the composite safety outcome of death, a serious adverse event, or a grade 3 or 4 adverse event (

166 rimary safety outcome (a composite of death, serious adverse events, or clinical grade 3 or 4 adverse

167 Only two serious adverse events, polycythaemia and urinary retent

168 Serious adverse event rates could not be determined with

169 adverse event (OR 2.30, 95% CI: 1.18-4.48), serious adverse events related to abnormal liver functio

170 Serious adverse events related to asfotase alfa occurred

171 There were no serious adverse events related to ChAdOx1 nCoV-19.

172 outcome was a composite of death, stroke, or serious adverse events related to rhythm-control therapy

173 not differ significantly between the groups; serious adverse events related to rhythm-control therapy

174 No unanticipated serious adverse events related to the implant or surgery

175 tions and infestations; pyrexia was the only serious adverse event reported in more than two patients

176 Compared to the sham group, there were more serious adverse events reported in the active treatment

177 There were no deaths or serious adverse events reported.

178 l outcome data at week 16-17, or sooner if a serious adverse event requiring knowledge of the study d

179 Four serious adverse events resulting in admission to hospita

180 In the intervention group, 0 serious adverse events resulting in death occurred vs 2

181 No procedure- or device-related serious adverse events resulting in vision loss occurred

182 One serious adverse event (SAE) that resulted in death was p

183 verall, 829 patients (13.5%) experienced >=1 serious adverse event (SAE), with infection the most com

184 PVR) is associated with a risk of procedural serious adverse events (SAE) and exposure to ionizing ra

185 The total incidence of AE and serious adverse events (SAE) was calculated.

186 Within clinical trials, rates of systemic serious adverse events (SAEs) after anti-VEGF treatment

187 . loa microfilariae (mf) density can develop serious adverse events (SAEs) after ivermectin treatment

188 ment outcomes, culture-conversion rates, and serious adverse events (SAEs) during treatment.

189 at Days 1, 28, 90, 180 and 210, adverse and serious adverse events (SAEs) to Study Day 210.

190 nth 36 in part 1, and symptomatic dengue and serious adverse events (SAEs) up to Month 36 in both par

191 ), and proportion of patients with 1 or more serious adverse events (SAEs) within 90 days (multiplici

192 Endpoints were solicited/unsolicited and serious adverse events (SAEs), biochemical/hematological

193 valescent plasma.RESULTSThe incidence of all serious adverse events (SAEs), including mortality rate

194 There were 39 serious adverse events (SAEs); SAEs believed to be direc

195 Thirty-nine episodes of serious-adverse-events(SAEs) were reported among 30(43%)

196 gs and are associated with increased risk of serious adverse events such as infusion reactions and an

197 One new serious adverse event suggestive of congestive heart fai

198 events and nine (21%) had treatment-related serious adverse events, the most frequent of which was p

199 65 (45%) patients had serious adverse events; the most frequent were abdominal

200 For serious adverse events, there was no clear dose-dependen

201 no device-related and four procedure-related serious adverse events through 6 months, and there were

202 Of the 16 serious adverse events unrelated to the study drugs, 4 (

203 Serious adverse events up to week 24 occurred in no pati

204 One serious adverse event was considered possibly related to

205 The most common treatment-related serious adverse event was hypokalaemia (four [1%] patien

206 At least one serious adverse event was reported by 21 (33%) participa

207 At least one treatment-related serious adverse event was reported in 25 (10%) patients

208 At least one serious adverse event was reported in 61 (68%) of 90 pat

209 CI 232.71-243.57) per 100 patient-years and serious adverse events was 12.63 (95% CI 11.41-13.94) pe

210 The rate of serious adverse events was 4.0 per 100 participants in t

211 The proportion of patients who suffered serious adverse events was 52% versus 41% (P = .096).

212 The proportion of patients with serious adverse events was higher in the cART arm (16%)

213 oportion of patients with 1 or more systemic serious adverse events was higher with bevacizumab than

214 The frequency of serious adverse events was low (four [1%] of 302) and si

215 The incidence of serious adverse events was low and similar across study

216 The incidence of serious adverse events was low and was similar in the va

217 The rate of serious adverse events was not significantly different b

218 p difference in the incidence or severity of serious adverse events was reported during the follow-up

219 The number of serious adverse events was similar in both groups and un

220 The percentage of children with serious adverse events was similar in the two groups (9.

221 The frequency of other serious adverse events was similar in the two groups.

222 The frequency of serious adverse events was similar in the two groups.

223 The incidence of serious adverse events was similar in the vaccine group

224 The most common treatment-related serious adverse events were abdominal pain in patients w

225 The most common serious adverse events were acute renal failure (41 [3.2

226 No serious adverse events were assessed as related to CYP-0

227 Serious adverse events were assessed in all women who re

228 Serious adverse events were associated with significantl

229 No serious adverse events were attributed to dihydroartemis

230 None of the serious adverse events were considered to be treatment r

231 The most common serious adverse events were hyperglycemia (12 patients w

232 No treatment-related serious adverse events were identified.

233 The most commonly reported serious adverse events were in the categories of infecti

234 The most common larotrectinib-related serious adverse events were increased alanine aminotrans

235 The most common serious adverse events were infections and infestations.

236 3.94) per 100 patient-years; the most common serious adverse events were infections at 4.13 (95% CI 3

237 The most common serious adverse events were lower respiratory tract infe

238 Adverse events and serious adverse events were minimal, but 2 deaths (7.4%)

239 Serious adverse events were more common with systematic

240 Serious adverse events were more frequent in the APOLLO-

241 No serious adverse events were noted after the booster dose

242 More serious adverse events were noted in the cisplatin plus

243 Serious adverse events were observed in 35 (39%) of 89 p

244 No relevant serious adverse events were observed in TCZ-treated pati

245 Serious adverse events were observed in ten (28%) patien

246 ents were related to (64)Cu-DOTATATE, and no serious adverse events were observed.

247 No unanticipated serious adverse events were observed.

248 No treatment-related serious adverse events were observed.

249 The most common grade 3 or worse serious adverse events were pregnancy, puerperium, and p

250 The most common serious adverse events were pyrexia (n=9), pneumonia (n=

251 Serious adverse events were rare, and the incidence was

252 Serious adverse events were recorded in 30 and 40 patien

253 No serious adverse events were related to the study treatme

254 No serious adverse events were related to vaccination.

255 Two serious adverse events were reported - both resolved wit

256 Serious adverse events were reported for 18 (20%) of 90

257 Serious adverse events were reported for 18 (8%) patient

258 Serious adverse events were reported for 79 patients (6.

259 Any-cause serious adverse events were reported in 121 (45%) patien

260 24 serious adverse events were reported in 17 (38%) of 45 p

261 Serious adverse events were reported in 30 (24%) of 127

262 Serious adverse events were reported in 36 (30%) of 121

263 Serious adverse events were reported in 4 (3%), 5 (3%),

264 e events possibly related to savolitinib and serious adverse events were reported in 62 (45%) patient

265 Serious adverse events were reported in 67 patients (10%

266 Serious adverse events were reported in 71 (40%) of 179

267 Serious adverse events were reported in 84 of 182 patien

268 Treatment-related serious adverse events were reported in eight (9%) of 85

269 Serious adverse events were reported in five (3%) of 156

270 No serious adverse events were reported in the eplerenone g

271 During the 2-year follow-up, 98 serious adverse events were reported in the HCO-HD group

272 nts were reported in the HCO-HD group and 82 serious adverse events were reported in the HF-HD group.

273 in the eplerenone group and three unrelated serious adverse events were reported in the placebo grou

274 Serious adverse events were reported infrequently.

275 Eight serious adverse events were reported with capsular relea

276 No serious adverse events were reported, and no participant

277 p (56.1% vs. 5.9%), but no treatment-related serious adverse events were reported.

278 no definitely vaccine-related withdrawals or serious adverse events were reported.

279 well tolerated and safe, and no drug-related serious adverse events were reported.

280 No treatment-related serious adverse events were reported; treatment-related

281 No treatment-related serious adverse events were seen.

282 Serious adverse events were similar across groups.

283 Adverse and serious adverse events were similar across the treatment

284 Serious adverse events were similar between groups (112

285 Serious adverse events were similar in both groups (vita

286 Cumulative rates of serious adverse events were similar in TAK-003 (4.0%) an

287 Adverse events and serious adverse events were similar in the two groups.

288 diplopia, and quality of life than placebo; serious adverse events were uncommon.

289 All 8 serious adverse events were unrelated to study products.

290 The most common serious adverse events were: in group A, pyrexia (three

291 25 (42%) patients reported at least one serious adverse event, which most commonly was an infect

292 ents experienced at least one device-related serious adverse event, which was classified as Grade III

293 36 individuals had 63 serious adverse events, which included 25 suicide attemp

294 34 (47%) patients had serious adverse events, which were considered to be avad

295 tation of the persistence of higher rates of serious adverse events with bevacizumab is uncertain bec

296 This approach predicts 53 serious adverse events with high positive predictive val

297 No serious adverse events with treatment or anesthesia were

298 in the safety analysis set had at least one serious adverse event (with 23 events in 19 [0.6%] patie

299 ied and 1812 (59.4%) of 3050 had one or more serious adverse events (with five events in five [0.2%]

300 erior with respect to access circuit-related serious adverse events within 30 days.